Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female between 18 and 70 years old~2. Patients with histologic proved metastatic breast cancer, unsuitable to be treated locally.~3. Patients with Her-2 negative breast cancer(HER-2 negative or one plus by IHC test , if HER-2 two plus by IHC,FISH result should be negative)~4. Disease progression after anthracycline and/or taxane regimen therapy and candidate for capecitabine monotherapy~5. Patients previously treated by capecitabine containing regimen should response to the chemotherapy containing capecitabine and progressed at least 4 months after the last capecitabine treatment~6. Karnofsky score more than 70；ECOG 0\~2；~7. Normal functions with heart, liver,renal and bone marrow~8. WBC≥4×109/L；Hb≥90 g/L；plt≥100×109/L~9. Got ICF before enrollment~Exclusion Criteria:~1. Pregnant or breast-feeding women or positive serum pregnancy test~2. Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling~3. Participation in any investigational drug study within 4 weeks preceding treatment start.~4. Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer.~5. Serious uncontrolled intercurrent infections~6. Poor compliance

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- experimental arm (Type: EXPERIMENTAL): capecitabine and pseudomonas aeruginosa combination

Based on this trial design, predict the completion outcome and termination type (if applicable).